A corporate venture capital fund invests globally in technologies with potential to impact mortality rates at scale by improving healthcare quality and outcomes to support the corporation’s goal of helping save 1M lives annually by 2030. This fund prioritizes technologies that address acute, time-critical conditions and makes investments internationally. The firm will invest up to $5M USD for their first check with capital reserved to follow on. The firm currently has 12 portfolio companies and is actively deploying capital.
The firm invests solely in medical devices, diagnostics, and digital health. The fund does not invest in therapeutics, biotech, pharma, and CROs. The fund looks at acute, time-critical areas of healthcare and is interested in solutions that support prevention, earlier identification and intervention, and improved therapeutics for these conditions. Key areas of focus include, but are not limited to cardiovascular care, sepsis, stroke, trauma and surgery, maternal and neonatal care, emergency medicine, and healthcare education & training.
The firm can act both as a lead and co-investor. The firm needs to see committed and full-time teams with demonstrated product market fit. The fund invests in pre- and post- FDA approval companies, but companies should have an MVP and licensed IP where relevant.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment